Evidence map›Paper›PMID 33791360›Full record

SynthesisBioMed research international2021

The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

Zhang Nan, Wang Guoqing, Yu Xiaoxu, Mi Yin, He Xin, Li Xue, Wang Rong

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Multi-omics profiling revealsTranslational lung cancer research · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Metabolic Tumor Volume Measured byJournal of hepatocellular carcinoma · 2023
    Article
  20. A Bioinformatic Analysis: The Overexpression and Prognostic Potential ofInternational journal of general medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhang NanDepartment of Clinical Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, China.ORCID https://orcid.org/0000-0001-6154-0383
Wang GuoqingTianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction; Tianjin Stomatological Hospital; Hospital of Stomatology, Nankai University, China.
Yu XiaoxuTianjin Central Hospital of Gynecology Obstetrics, China.
Mi YinDepartment of Radiotherapy, First Affiliated Hospital of Zhengzhou University, China.
He XinDepartment of Clinical Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, China.
Li XueSchool of Medical Laboratory, Tianjin Medical University, China.
Wang RongSchool of Medical Laboratory, Tianjin Medical University, China.ORCID https://orcid.org/0000-0003-3502-5446

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNonsmall cell lung cancer (NSCLC) is the most common type of lung cancer, and the majority of NSCLC patients are diagnosed at the advanced stage. Chemotherapy is still the main treatment at present, and the overall prognosis is poor. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors (ICIs) as the representative have been extensively applied for treating various types of cancers. Tumor mutation burden (TMB) as a potential biomarker is used to screen appropriate patients for treatment of ICIs. To verify the predictive efficacy of TMB, a systematic review and meta-analysis were conducted to explore the association between TMB and ICIs.

methodPubMed, EMBASE, Cochrane Library, and son on were systematically searched from inception to April 2020. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were estimated.

resultsA total of 11 studies consisting of 1525 nonsmall cell lung cancer (NSCLC) patients were included. Comparison of high and low TMB: pooled HRs for OS, 0.57 (95% CI 0.32 to 0.99;

conclusionsThese findings imply that NSCLC patients with high TMB possess significant clinical benefits from ICIs compared to those with low TMB. As opposed to bTMB, tTMB was thought more appropriate for stratifying NSCLC patients for ICI treatment.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansImmune Checkpoint InhibitorsProgression-Free SurvivalSurvival RateBiomarkers, TumorImmune Checkpoint Inhibitors

Identifiers

PMID33791360
PMCPMC7984892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.